Liver transplant diabetes study tests which drug better fights fatty liver

This study looked at 100 liver transplant patients with diabetes to see if dapagliflozin or sitagliptin is better at reducing liver fat and improving body composition. Participants took one of the two drugs for 12 months. The goal was to find a safer and more effective way to manage diabetes and prevent fatty liver after transplant, since these patients must take lifelong immunosuppressants that raise blood sugar.